Enrollment goal met in trial of individualized ADT/RT for high-risk prostate cancer

高风险前列腺癌的个体化ADT/RT治疗试验已满员。为评估高风险前列腺癌患者是否可以根据Decipher基因检测结果分配到减轻或加强的并发激素治疗和放射治疗 regimen。该试验 enroll 2478名成人患者，患者将进行Decipher基因检测，以确定是否将分配到减轻或加强治疗。该试验旨在改善高风险前列腺癌患者的生活质量和结果，同时根据每个个体的需要分配治疗。

来源: urologytimes

原文链接：原文

参考文献

1. NRG Oncology PREDICT-RT study completes patient accrual, tests individualized concurrent therapy and radiation for high-risk prostate cancer. News release. NRG Oncology. September 18, 2025. Accessed September 26, 2025. https://www.eurekalert.org/news-releases/1098858
2. Two studies for patients with high risk prostate cancer testing less intense treatment for patients with a low gene risk score and testing a more intense treatment for patients with a high gene risk score, the PREDICT-RT trial. ClinicalTrials.gov. Last updated September 11, 2025. Accessed September 26, 2025. https://clinicaltrials.gov/study/NCT04513717